PMID- 30539834 OWN - NLM STAT- MEDLINE DCOM- 20190218 LR - 20220330 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 14 IP - Supplement DP - 2018 Dec TI - Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model. PG - S985-S992 LID - 10.4103/0973-1482.192765 [doi] AB - PURPOSE: To investigate the effects of dalteparin sodium on the expression of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), and hypoxia-inducible factor 1alpha (HIF-1alpha) in A549 human lung cancer (LC) cell line and a human A549-grafted nude mouse model. MATERIALS AND METHODS: A549 human lung adenocarcinoma cell line was divided into control group, treated using normal saline (NS); and dalteparin sodium groups, receiving 5, 15, 50, and 150 IU/ml of dalteparin sodium, respectively. Human A549-grafted nude mouse was induced through subcutaneous (SC) injection of A549 (5 x 10(6)/0.2 ml) into the right armpit, and randomly assigned into control group (n = 6) receiving intraperitoneal (i.p.) injection of NS, cisplatin (DDP) group (n = 6, 3 mg/kg DDP alone, i.p., for 3 days), low molecular weight heparin (LMWH) group (n = 6) receiving SC injection of 1500 IU/kg dalteparin sodium for 35 days, and DDP plus LMWH group (n = 6, 3 mg/kg DDP, i.p., for 3 days, followed by SC injection of 1500 IU/kg dalteparin sodium for 35 days). RESULTS: Significant difference was noted in the messenger RNA expression of VEGF, VEGFR, and HIF-1alpha after treating with heparin with a concentration of 15, 50, or 150 IU/ml in the A549 cell line at 24 and 48 h, respectively. In the human A549-grafted nude mouse model, a significant reduction was noted in the expression of VEGF, VEGFR, and HIF-1alpha in the tumor mass harvested from the mice receiving administration of dalteparin sodium plus DDP. CONCLUSION: Dalteparin sodium had the inhibitory effects on the growth of human LC A549 cells in vitro and A549 LC xenograft model, which could be enhanced when administrated together with DDP. FAU - Rui, Yan AU - Rui Y AD - Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical College, Lung Cancer Diagnosis and Treatment Center of Anhui Province, Anhui Provincial Key Laboratory of Clinical Basic Research on Respiratory Disease, Bengbu, China. FAU - Wang, Dongsheng AU - Wang D AD - Department of Respiration, Anhui Provincial Hospital, Hefei, China. FAU - Hu, Danfeng AU - Hu D AD - Department of Respiration, The Third People's Hospital of Bengbu, Bengbu, China. FAU - Huang, Linian AU - Huang L AD - Department of Respiration, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 RN - 0 (VEGFA protein, human) RN - 0 (Vascular Endothelial Growth Factor A) RN - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor) RN - Q20Q21Q62J (Cisplatin) RN - S79O08V79F (Dalteparin) SB - IM MH - A549 Cells MH - Animals MH - Antineoplastic Combined Chemotherapy Protocols/*pharmacology/therapeutic use MH - Cell Proliferation/*drug effects MH - Cisplatin/pharmacology/therapeutic use MH - Dalteparin/*pharmacology/therapeutic use MH - Drug Synergism MH - Female MH - Humans MH - Lung Neoplasms/blood supply/*drug therapy/pathology MH - Mice MH - Mice, Inbred BALB C MH - Mice, Nude MH - Neovascularization, Pathologic/*drug therapy/pathology MH - Receptors, Vascular Endothelial Growth Factor/metabolism MH - Treatment Outcome MH - Vascular Endothelial Growth Factor A/metabolism MH - Xenograft Model Antitumor Assays OTO - NOTNLM OT - Dalteparin sodium OT - hypoxia-inducible factor-1alpha OT - nonsmall cell lung cancer OT - nude mice OT - vascular endothelial growth factor COIS- None EDAT- 2018/12/13 06:00 MHDA- 2019/02/20 06:00 CRDT- 2018/12/13 06:00 PHST- 2018/12/13 06:00 [entrez] PHST- 2018/12/13 06:00 [pubmed] PHST- 2019/02/20 06:00 [medline] AID - JCanResTher_2018_14_12_985_192765 [pii] AID - 10.4103/0973-1482.192765 [doi] PST - ppublish SO - J Cancer Res Ther. 2018 Dec;14(Supplement):S985-S992. doi: 10.4103/0973-1482.192765.